Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients (TICTAC)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by Newark Beth Israel Medical Center.
Recruitment status was  Active, not recruiting
Astellas Pharma Inc
Information provided by:
Newark Beth Israel Medical Center Identifier:
First received: March 2, 2006
Last updated: March 29, 2010
Last verified: February 2009